A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)
Phase 1
Recruiting
- Conditions
- Primary Sclerosing Cholangitis (PSC)MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2023-507027-37-00
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method